PREE RELEASE \u2013 Berlin\/Germany, 4 November 2019<\/p>\n
When mdbrain 1.0 was launched in January 2019 as the first product of the young company mediaire, the strong focus was on supporting the diagnosis of dementia by quantifying brain volume (volumetry).<\/p>\n
Based on customer feedback, new features were added to provide radiologists with a more powerful tool \u2013 mdbrain 2.0. It not only supports volumetric analysis of brain structures, but also allows the characterization of brain lesions for static and longitudinal studies. Such lesions are characteristic for diseases like Multiple Sclerosis and are important for diagnosis and follow up of patients living with this condition.<\/p>\n
\u201cWe are very proud to now offer a robust tool for lesion characterization which also allows the assessment of lesion dynamics over time. While the radiologist is relieved from the time-consuming task of counting lesions, the neurologist can now make treatment decisions based on hard facts.\u201d explains Dr Andreas Lemke, the CEO of mediaire.<\/p>\n
Besides the new functionalities, mdbrain\u2019s AI-algorithms have also been improved and their sample of healthy normal people has increased by several thousand.<\/p>\n
\u201cThis allows us to calculate individual normal values for several brain regions comparable to lab reports. By accounting for age, sex & skull volume we can see within an age range of 18 and over 90 years whether a patient has an abnormal low brain volume corresponding to potential dementia.\u201d describes Dr. Lemke further.<\/p>\n
For interested professionals mediaire offers a free trial of its mdbrain software.<\/p>\n
Download full press release here:<\/p>\n